Pharvaris (NASDAQ:PHVS) Shares Gap Down – Here’s What Happened

Posted by Brian Himes on Mar 19th, 2025

Shares of Pharvaris (NASDAQ:PHVS – Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $16.67, but opened at $16.23. Pharvaris shares last traded at $16.77, with a volume of 4,984 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, JMP Securities upped their target price on Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a research note on Friday, January 31st.

View Our Latest Report on Pharvaris

Pharvaris Trading Down 3.3 %

The business has a 50 day moving average of $17.03 and a 200-day moving average of $19.11. The stock has a market cap of $834.55 million, a PE ratio of -5.70 and a beta of -3.02.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in Pharvaris in the 3rd quarter valued at $526,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Pharvaris in the 3rd quarter valued at $906,000. State Street Corp acquired a new position in Pharvaris in the 3rd quarter valued at $1,000,000. Geode Capital Management LLC raised its holdings in Pharvaris by 18.4% in the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock valued at $685,000 after acquiring an additional 5,753 shares during the last quarter. Finally, Barclays PLC acquired a new position in Pharvaris in the 3rd quarter valued at $106,000.

About Pharvaris

(Get Free Report)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.